Renal Cell Carcinoma
Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. T...
Saved in:
| : | |
|---|---|
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (500 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993548201904498 |
|---|---|
| ctrlnum |
(CKB)4100000011302268 (oapen)https://directory.doabooks.org/handle/20.500.12854/58186 (EXLCZ)994100000011302268 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
López, José I. auth Renal Cell Carcinoma MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (500 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews. English Renal cell carcinoma. Kidneys Cancer. N-glycomapping SMAD proteins patient survival pro-IL-1? survival prediction inflammation markers tumor migration prognostic factors practical approach circular RNAs in a clinico-genomic predictive model glycomarkers review nephrectomy uric acid VEGF inhibitors metabolic reprogramming collecting duct carcinoma curcumin metabolome profiling identification of circular RNAs IL-2 experimental validation of circular RNA Raf/MEK/ERK HOT PI3K/Akt/mTOR pentose phosphate pathway kidney cancer LOT mutation RCC polybromo-1 pale cell MMP-9 gene expression recurrence free survival chromosomal loss IL-1? chronic kidney disease glutathione transferase omega 2 label-free glutathione transferase omega 1 emerging entity copy number alteration FOXO3 predictive role tumor slice culture tyrosine kinase inhibitors PPP ESC CDKN1A expression metastasis PD-L1 diagnostic and prognostic markers EVI1 copy number loss RNA sequencing NK cells glutathione metabolism clear cell renal cell carcinoma renal cell cancer proliferation eosinophilic variant Xp11 translocation renal cell carcinoma prognosis invasion immune infiltration IL4R? FISH 11) translocation renal cell carcinoma tumor microenvironment metabolome hyperosmolality toxicity ALK drug sensitivity t(6 copy number analysis urine genetic association polymorphism solute carrier proteins kidney metastatic ccRCC molecular genetic features recurrence-free survival chromophobe renal cell carcinoma unclassified renal tumor overall survival mTOR inhibitors mTOR JAK2 von Hippel-Lindau miR-155-5p glycoproteomics PBRM1 miR-133b survival TFE3 TFEB oncocytic renal tumor immune checkpoint inhibitors biomarker MMP10 TCGA ghrelin EMT like checkpoint inhibitors MiT family translocation renal cell carcinoma gene signature sarcomatoid transforming growth factor beta clear cell Renal Cell Carcinoma tumor adhesion renal cancer unclassified renal cell carcinoma Papillary renal cell carcinoma (pRCC) miR-146a-5p renal cell everolimus integrins cytoreductive nephrectomy immunotherapy predictive factors immunohistochemistry MTA2 IL13R?1 targeted therapy intratumour heterogeneity aurora A TCA cycle AMP-activated protein kinases cancer-specific survival programmed death-ligand 1 efficacy renal cell carcinoma anaplastic lymphoma kinase rearrangement TFEB-amplified renal cell carcinoma statins cancer immunotherapy microRNA new entity proteome profiling 9783039286386 |
| language |
English |
| format |
eBook |
| author |
López, José I. |
| spellingShingle |
López, José I. Renal Cell Carcinoma |
| author_facet |
López, José I. |
| author_variant |
j i l ji jil |
| author_sort |
López, José I. |
| title |
Renal Cell Carcinoma |
| title_full |
Renal Cell Carcinoma |
| title_fullStr |
Renal Cell Carcinoma |
| title_full_unstemmed |
Renal Cell Carcinoma |
| title_auth |
Renal Cell Carcinoma |
| title_new |
Renal Cell Carcinoma |
| title_sort |
renal cell carcinoma |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2020 |
| physical |
1 electronic resource (500 p.) |
| isbn |
3-03928-639-0 9783039286386 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT lopezjosei renalcellcarcinoma |
| status_str |
n |
| ids_txt_mv |
(CKB)4100000011302268 (oapen)https://directory.doabooks.org/handle/20.500.12854/58186 (EXLCZ)994100000011302268 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Renal Cell Carcinoma |
| _version_ |
1796652178408996864 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06861nam-a2201993z--4500</leader><controlfield tag="001">993548201904498</controlfield><controlfield tag="005">20231214133603.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03928-639-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000011302268</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/58186</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000011302268</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">López, José I.</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Renal Cell Carcinoma</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (500 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Renal cell carcinoma.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Kidneys</subfield><subfield code="x">Cancer.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">N-glycomapping</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SMAD proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">patient survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pro-IL-1?</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival prediction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation markers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor migration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">practical approach</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">circular RNAs in a clinico-genomic predictive model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">review</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nephrectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">uric acid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VEGF inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolic reprogramming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">collecting duct carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">curcumin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolome profiling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">identification of circular RNAs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">experimental validation of circular RNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Raf/MEK/ERK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HOT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K/Akt/mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pentose phosphate pathway</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">kidney cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LOT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polybromo-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pale cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MMP-9</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recurrence free survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chromosomal loss</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL-1?</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic kidney disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glutathione transferase omega 2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">label-free</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glutathione transferase omega 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">emerging entity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">copy number alteration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FOXO3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive role</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor slice culture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PPP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ESC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CDKN1A expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diagnostic and prognostic markers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EVI1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">copy number loss</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NK cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glutathione metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clear cell renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proliferation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">eosinophilic variant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Xp11 translocation renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">invasion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune infiltration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL4R?</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FISH</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">11) translocation renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hyperosmolality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">toxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ALK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug sensitivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">t(6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">copy number analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic association</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polymorphism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">solute carrier proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">kidney</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic ccRCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular genetic features</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recurrence-free survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chromophobe renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">unclassified renal tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">overall survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">JAK2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">von Hippel-Lindau</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miR-155-5p</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycoproteomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PBRM1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miR-133b</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TFE3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TFEB</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncocytic renal tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MMP10</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TCGA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ghrelin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EMT like</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MiT family translocation renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene signature</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sarcomatoid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transforming growth factor beta</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clear cell Renal Cell Carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor adhesion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">unclassified renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Papillary renal cell carcinoma (pRCC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miR-146a-5p</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">everolimus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">integrins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytoreductive nephrectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MTA2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL13R?1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intratumour heterogeneity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aurora A</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TCA cycle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AMP-activated protein kinases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer-specific survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">programmed death-ligand 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">efficacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anaplastic lymphoma kinase rearrangement</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TFEB-amplified renal cell carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">statins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">new entity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proteome profiling</subfield></datafield><datafield tag="776" ind1="0" ind2=" "><subfield code="z">9783039286386</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:58:36 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-06-20 22:16:43 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338733130004498&Force_direct=true</subfield><subfield code="Z">5338733130004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338733130004498</subfield></datafield></record></collection> |